At almost $2,200 a pop, it’s probably no surprise that we get lots of questions about generic Lucentis. If you are an age-related macular degeneration (AMD) patient, Lucentis is the only FDA-approved treatment for the wet-form of AMD, but unfortunately, it’s also incredibly pricey, so we get questions all the time about What’s going on . . . → Read More: Will Generic Lucentis Ever Be Available in the U.S.?
Remember that $1.3 billion in health insurance rebates? They haven’t been in the news lately much because we’ve all been watching the Supreme Court for their ruling on the Affordable Care Act (“Obamacare”). Well, health insurers have been sitting on those rebates, and it turns out there’s probably a good reason.
Health insurers were being . . . → Read More: Supreme Court Ruling: What Will Happen to the $1.3 Billion In Health Insurance Rebates?